Skip to main content
Guilin Sanjin Pharmaceutical Co.,Ltd logo

Guilin Sanjin Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 002275 ISIN · CNE100000DY9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,174 across all filing types
Latest filing 2026-05-19 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002275

About Guilin Sanjin Pharmaceutical Co.,Ltd

https://www.sanjin.com.cn

Guilin Sanjin Pharmaceutical Co.,Ltd. specializes in the research, development, and manufacturing of proprietary Chinese medicines and natural health products. The company is recognized for its integration of traditional herbal formulas with modern pharmaceutical technology. Its core product portfolio includes the Sanjin Tablet series, primarily used for treating urinary tract infections, and the Guilin Watermelon Frost series, widely utilized for oral and throat ailments. The firm operates advanced production facilities and maintains a strong focus on innovation within the field of modern Traditional Chinese Medicine (TCM). Its product range extends to various therapeutic areas, including cardiovascular health and internal medicine, catering to both domestic and international markets through a commitment to quality and standardized production processes.

Recent filings

Filing Released Lang Actions
北京市通商律师事务所关于桂林三金药业股份有限公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a legal opinion letter on the company’s 2025 annual general meeting that includes detailed vote counts and resolutions for each agenda item. It serves as the official declaration of voting results at the AGM rather than the AGM materials themselves, a financial report, or a mere announcement. Therefore it best fits the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-19 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled “2025年度股东会决议公告” and details the proposals submitted at the annual general meeting, including precise vote counts (agree/oppose/abstain) for each resolution. It is an official announcement of shareholder voting results rather than the meeting presentation materials or a full annual report. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-19 Chinese
关于召开2025年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 85% confidence The document is an announcement by Guilin Sanjin Pharmaceutical Co., Ltd. regarding an upcoming “业绩说明会” (performance explanation meeting) for the 2025 annual and 2026 Q1 results. It is not the report itself but an investor‐facing presentation event, not a simple publication notice of a report. Therefore it best fits the “Investor Presentation” category (IP).
2026-05-13 Chinese
关于为孙公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 桂林三金药业股份有限公司 regarding the progress of guarantees provided for its subsidiary. It details the amounts, terms, and approvals related to guarantees extended to a subsidiary for loans from banks. The document includes specific guarantee contract details, guarantee amounts, and board approvals. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about financing guarantees and related risk disclosures. The document length is 2330 characters, relatively short and focused on guarantee progress and risk disclosure. This fits the category of Capital/Financing Update (CAP), which covers updates on company financing activities and guarantees. Therefore, the appropriate classification is CAP with high confidence.
2026-03-27 Chinese
关于为孙公司提供担保的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 桂林三金药业股份有限公司 regarding the progress of providing guarantees for its subsidiary. It details the guarantee amount, the parties involved, the guarantee contract, and the current status of guarantees. The document is relatively short (1667 characters) and focuses on a specific financial guarantee update rather than a full financial report or audit. It does not contain financial statements or comprehensive financial data. It is a regulatory announcement about a financing-related guarantee activity, but it is not a full Capital/Financing Update report. Given the content and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about guarantees and risk disclosures, which do not fit other specific categories.
2026-02-27 Chinese
北京市通商律师事务所关于桂林三金药业股份有限公司2025年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the convening, attendance, voting procedures, and results of the 2025 second extraordinary general meeting (临时股东大会) of Guilin Sanjin Pharmaceutical Co., Ltd. It details the voting results on various proposals, including amendments to company bylaws, election of board members, and other governance matters. The document is not a report of financial performance, audit, or earnings, but rather a legal certification and validation of the shareholder meeting and its outcomes. It is not a simple announcement but a detailed legal opinion on the meeting's procedures and results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official voting results and legal validation of the shareholder meeting decisions.
2025-12-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.